share_log

Guggenheim Initiates Coverage On Medicenna Therapeutics With Buy Rating, Announces Price Target of C$2

Guggenheim Initiates Coverage On Medicenna Therapeutics With Buy Rating, Announces Price Target of C$2

古根海姆以購買評級啟動 Medenna 治療藥物的覆蓋範圍,宣布目標為 C 2 美元
Benzinga Real-time News ·  2022/11/29 20:55

Guggenheim analyst Charles Zhu initiates coverage on Medicenna Therapeutics (TSX:MDNA) with a Buy rating and announces Price Target of C$2.

古根海姆分析師朱查爾斯(Charles Zhu)以「買入」評級啟動了 Medenna 治療(TSX:MDNA)的報導,並宣布目標價格為 C 2 美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論